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Abstract 
Herein we report X-ray crystal structures of 11-13 residue antimicrobial peptides (AMPs) 
active against Pseudomonas aeruginosa as complexes of fucosylated D-enantiomeric 
sequences with the P. aeruginosa lectin LecB. These represent the first crystal structures of 
short AMPs. In twenty-four individual structures of eight different peptides we found mostly 
α-helices assembled as two-helix or four-helix bundles with a hydrophobic core and cationic 
residues pointing outside. Two of the analogs formed an extended structure engaging in 
multiple contacts with the lectin. Molecular dynamics (MD) simulations showed that α-
helices are stabilized by bundle formation and suggested that the N-terminal acyl group 
present in the linker to the fucosyl group can extend the helix by one additional H- bond and 
increase α-helix amphiphilicity. Investigating N-terminal acylation led to AMPs with 
equivalent and partly stronger antibacterial effects compared to the free peptide.  
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Introduction 
The emergence of multidrug resistant (MDR) Gram-negative bacteria such as Pseudomonas 
aeruginosa and Acinetobacter baumannii in the hospital environment is calling for the 
development of new antibacterial agents.(1-3) Antimicrobial peptides (AMPs), which occur in 
microorganisms, plants and animals as components of innate immunity, offer a promising 
opportunity to address this challenge.(4-6) Many of these AMPs are short peptides which fold 
into amphiphilic α-helices in contact with the bacterial membrane,(7-14) leading to 
aggregation inducing membrane disruption, morphological changes and cell lysis as 
documented by imaging studies.(15-18) Such short AMPs can exert potent effect against 
multidrug resistant bacteria and their biofilms,(19, 20) and show potent activities in vivo.(21) 
Interestingly, the experimental evidence for α-helix formation in these peptides is mostly 
based on circular dichroism (CD) and NMR studies.(22) Direct crystallographic evidence for 
α-helices in short AMPs(23) has only been reported for mastoparan MP-PJ (14 residues),(24) 
mellitin (26 residues), toxic to both prokaryotic and eukaryotic cells,(25) and an analog of 
magainin II (23 residues) with a crystal structure of the racemic form,(26) as well as for 
peptaibols, a special class of non-ribosomal peptides forming ion channels and which fold 
into an unusual 310-helix induced by amino-isobutyric acid residues.(27-29)  
 Herein we report X-ray crystal structures of analogs of the 13 residue peptide 
KYKKALKKLAKLL (SB1), initially reported by Hancock and coworkers to be active 
against P. aeruginosa,(30) in form of complexes of fucosylated D-enantiomeric sequences 
(e.g. SB4, Scheme 1) with P. aeruginosa lectin LecB.(31) These are the first X-ray crystal 
structures of short α-helical AMPs targeting Gram-negative bacteria. This report builds on our 
previous examples of using LecB complexes to access structural data for molecules otherwise 
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difficult to crystallize such as oligonucleotides,(32) glycopeptide dendrimer biofilm 
inhibitors,(33-39) cyclic and bicyclic AMPs.(40, 41)    
 The fucosylated peptides reported here act similarly to SB1 by folding into 
amphiphilic and membrane disruptive helices. The crystal structures of their LecB complexes 
show that they mostly form α-helices assembled via hydrophobic contacts into two-helix or 
four-helix bundles, although two sequences present an unfolded extended structure in their 
LecB complexes. Molecular dynamics (MD) simulations show that α-helices are stabilized by 
bundle formation in the crystal but are not stable in pure water as single entities. They also 
suggest that the N-terminal acyl group added as a linker to the fucosyl group can extend the 
helix by one additional H-bond and thereby increase α-helix amphiphilicity. Investigating N-
terminal acylation led to AMP analogs displaying equivalent and partly stronger antibacterial 
effects against different Gram-negative strains as well as P. aeruginosa biofilm inhibition 
compared to the free peptide.  
 
 
Scheme 1. Synthesis of AMP SB4. Conditions: a. (i) Piperidine/DMF (1/4; v/v), RT, 2x 20 min, (ii) 
FmocAAOH, oxyma/DIC (3 eq), NMP/DCM (6/1, v/v); RT, 1.5 h. b. Peracetylated α-L-fucosyl-acetic acid, 
oxyma/DIC (5 eq), NMP/DCM (6/1, v/v), RT, overnight. c. MeOH/H2O/25% NH4OH (8:1:1, v/v/v), 12 h. d. 
TFA/TIS/H2O (94:5:1, v/v/v), 3 h. 
 
4 
 
Results and Discussion 
Synthesis of SB1 and analogs 
Aiming to perform functional and structural studies we prepared the 13-mer AMP SB1 and its 
D-enantiomer SB2 as well as the corresponding N-terminally C-fucosylated derivatives SB3 
and SB4 by N-terminal acylation using peracetylated α-C-fucosylacetic acid as described 
previously for peptide dendrimers (Scheme 1).(42) We also prepared shorter fucosylated 
analogs focusing on D-enantiomeric sequences because fucosylated L-sequences only 
generated few diffracting crystals where the peptides were not resolved. Specifically, we 
removed one or two residues at each end of the peptide to test the dependence of folding on 
sequence length (SB5-SB9). Furthermore, we synthesized the retro-inverso sequence (SB10) 
and its shortened analogs (SB11-SB15) to investigate folding in a modified context. 
Following our structural studies, we finally prepared N-terminally acylated analogs SB16-
SB18 to test the influence of this modification on folding and activity (Table 1). 
 
SB1 is a typical membrane disruptive AMP 
The 13-residue AMP SB1 is predicted to fold into an amphiphilic α-helix clustering cationic 
and hydrophobic side chains on opposite sides of the helix (Figure 1a). Analysis of CD 
spectra using Dichroweb(43) showed a transition from a disordered conformation in water to 
an α-helical conformation upon addition of up to 20% v/v trifluoroethanol (TFE), which 
partly mimics the reduced polarity environment of the bacterial membrane. This behavior is 
typical of short amphiphilic and membrane disruptive AMPs (Figure 1b).(5, 44) As expected 
from this folding behavior, SB1 exhibited membrane disruptive activity in vesicle leakage 
experiments with vesicles consisting of phosphatidyl glycerol (PG) mimicking the bacterial 
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membrane (Figure 1c). Vesicles consisting of phosphatidyl choline (PC) similar to the 
membrane of eukaryotic cells were also affected (Figure 1d), although SB1 showed negligible 
hemolysis (Table 1). The D-enantiomeric sequence SB2 showed similar folding and 
membrane disruptive properties.  
 
Table 1. Sequences, α-helical content and activity of SB1 and C-fucosylated analogs on P. aeruginosa. 
Cpd. Sequencea) Nb) % α-helixc) Vesicle leakage (%)d) MHC 
(µg/mL)e) 
MIC 
(µg/mL)f) 0% TFE 20% TFE PG PC 
SB1 KYKKALKKLAKLL 13 12 63 60 45 >2000 2 
SB2 kykkalkklakll 13 9 69 70 30 >2000 1 
SB3 *KYKKALKKLAKLL 13 n.d. n.d. n.d. n.d. n.d. n.d. 
SB4 *kykkalkklakll 13 11 68 41 10 1000 4 
SB5 *ykkalkklakll 12 11 66 76 11 500 8 
SB6 *kykkalkklakl 12 12 48 60 0 >2000 64 
SB7 *kykkalkklak 11 11 33 6 2 >2000 >64 
SB8 *kkalkklakll 11 13 53 57 3 >2000 32 
SB9 *ykkalkklakl 11 11 47 70 1 >2000 64 
SB10 *llkalkklakkyk 13 9 60 37 4 1000 n.d. 
SB11 *llkalkklakky 12 11 64 49 10 1000 16 
SB12 *lkalkklakkyk 12 9 42 25 0 >2000 64 
SB13 *kalkklakkyk 11 10 29 3 0 >2000 64 
SB14 *llkalkklakk 11 11 56 22 1 >2000 32 
SB15 *lkalkklakky 11 11 50 61 1 >2000 32 
SB16 Ac-kykkalkklakll 13 13 63 75 32 500 2 
SB17 Pr-kykkalkklakll 13 15 68 71 35 500 2 
SB18 C8-kykkalkklakll 13 14 60 31 99 16 2 
a) Single letter code for amino acids, * indicates a C-fucosyl group as shown in Scheme 1. Ac=acetyl, Pr=propyl, 
C8=octanoyl. b) Number of amino acids. c) CD spectra were recorded at 0.1 µg/mL in aq. 10 mM phosphate buffer pH 7.2 
with addition of 0, 5, 10, 15 and 20 % v/v trifluoroethanol (TFE). The primary CD spectra were analyzed using DichroWeb, 
and the percentages of α-helical signals were extracted. The full table is shown in the SI (Table S2). The Contin-LL method 
and reference set 4 were used.(43) n.d. = not determined. d) Membrane disruption was assessed on phosphatidyl glycerol 
(PG) or phosphatidyl choline (PC) lipid vesicles loaded with 50 mM 5(6)-carboxyfluorescein buffer and treated with peptide 
solutions (45 s) and 1.2% Triton X-100 (285 s). The percentage of lysis at 10 µg/mL was determined as It/I∞ where It is the 
fluorescence intensity at t = 250 s and I∞ is the fluorescence at t = 350 s. e) Minimum hemolytic concentration (MHC, 
µg/mL) was measured on human red blood cells in phosphate buffered saline at room temperature for 4 hours. All 
experiments were done in at least two independent duplicates. f) Minimum inhibitory concentration (MIC, µg/mL) was 
measured in Mueller-Hinton medium on P. aeruginosa PAO1, after incubation for 16-20 h at 37 °C. Values were obtained 
from at least 2 independent duplicate experiments giving the same results. 
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Figure 1. Evidence for α-helical folding and membrane disruption by the 13-residue AMP SB1.  a) Prediction of 
SB1 with α-helix wheel. b) CD spectra of SB1 in phosphate buffer pH7.2 with 0, 5, 10, 15 and 20% v/v 2,2,2-
trifluoroethanol. 5(6)-Carboxyfluorescein leakage from c) phosphatidylglycerol (PG) and d) phosphatidylcholine 
(PC) lipid vesicles. Addition of SB1 to a lipid vesicle solution in buffer (10 mM TRIS, 107 mM NaCl, pH 7.4) at 
45 s and addition of 1.2% Triton X-100 at 285 s. 
 
Fucosylated D-peptide SB4 is a membrane disruptive AMP 
The N-terminally fucosylated D-enantiomeric sequence SB4 and the fucosylated retro-inverso 
sequence SB10 showed a folding and membrane disruptive behavior similar to the parent 
sequence SB1 (Table 1, Figure S1, Supplementary Table S2 and Figure S3). α-Helical folding 
was significantly reduced upon sequential removal of leucine residues at the C-terminus 
(SB4→SB6→SB7) respectively at the N-terminus of the retro-inverso sequence 
(SB10→SB12→SB13), in agreement with the α-helix propensity of leucine. Furthermore, 
membrane disruption as measured by vesicle leakage was strongly reduced for SB7 and SB13 
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lacking both terminal leucine residues and showing negligible α-helical folding with TFE. 
None of the fucosylated sequences showed any significant hemolysis. Remarkably, the 
fucosylated analog SB4 of the parent AMP showed the same minimum inhibitory 
concentration (MIC) against P. aeruginosa PAO1 as the parent AMP, however the activity 
was strongly reduced in all modified sequences. Taken together, these data showed that the 
fucosylated AMP SB4 behaved as a membrane disruptive AMP similarly to the parent 
sequence.  
 
SB4 forms a four-helix bundle as LecB complex 
Crystallization attempts with the full sequence SB1 or its D-enantiomer SB2, the racemic 
mixture of both, or with the fucosylated L-enantiomer SB3 in complex with LecB were 
unsuccessful. By contrast, we obtained good quality diffraction data of LecB complexes with 
the fucosylated analog SB4 (2.01 Å, PDB 6Q86, Table S4.1 and Figure 2, and 2.01 Å, PDB 
6Q79, Supplementary Table S3, Table S4.2 and Figure S5.2). In these two structures, SB4 
peptides are bound to LecB monomers at their fucose binding sites via the N-terminal fucose 
and folded into fully or partially resolved amphiphilic α-helices, with two (PDB 6Q86) 
respectively four (PDB 6Q79) non-equivalent SB4 peptides in the asymmetric unit. In both 
structures, there are no contacts between the peptide portion of the ligands and the protein, 
suggesting that folding occurs independently of the lectin. The two respectively four non-
equivalent α-helices form four-helix bundles in which hydrophobic residues are packed on the 
inside and cationic, hydrophilic residues face outwards. In the first structure (PDB 6Q86), the 
four peptides forming the bundle are complete. However, in the second case (PDB 6Q79), 
only two of the α-helices are entirely resolved and well-formed, while the other two are only 
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observed for the six N-terminal residues preceding the fucosyl group, which can be 
interpreted in terms of a partially folded α-helix with a disordered C-terminus.  
 
Figure 2. Details of the first X-ray structure of the SB4·LecB complex (PBD 6Q86) (a-b) The two non-
equivalent peptides with electron density map as blue mesh, Ca2+ atoms shown as magenta spheres and the 
bound LecB monomer as green cartoon. (c) Charge distribution within the 4-helix bundle. Hydrophobic side 
chains are colored brown and cationic side chains in blue. Backbone atoms are shown as cartoon. (d) Overview 
of the 4-helix bundle in the crystal. Each of the four peptide (spheres) - LecB monomer (cartoon) complexes is 
independently color-coded. 
 
SB4 analogs form helix-bundles or extended structures as LecB complexes 
We next investigated shortened and retro-inverso sequences SB5-SB15 to test if additional 
peptide conformations might occur in LecB complexes besides the fully and partially folded 
α-helices observed in the two structures of SB4·LecB. While we did not obtain any crystals 
for the least helical and inactive peptides SB7 and SB13, or for SB9 and SB14 which also 
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belonged to the shortest and least helical sequences, the remaining seven fucosylated D-
peptides SB5, SB6, SB8, SB10, SB11, SB12 and SB15 yielded well diffracting crystals as 
complexes with LecB (Supplementary Table S3, Tables S4.3-4.10). These crystals revealed 
one to four different individual peptide structures each depending on crystal symmetry. In 
most cases the entire peptide sequence was well resolved (Supplementary Figures S5.3-5.10, 
Figure 3).  
 A detailed analysis of peptide conformations in the different structures showed that 
almost all residues were in an α-helical conformation as indicated by their Ramachandran 
angles (Supplementary Table S5). LecB complexes with SB5, SB6, SB8, SB10 and SB11 
were globally comparable to the two SB4·LecB structures and showed α-helical peptides 
engaging in two-helix or four-helix bundles with a hydrophobic core and hydrophilic residues 
on the outside (Supplementary Figures S5.3-5.8). As observed with SB4 the helices did not 
form significant contacts with LecB. In fact, for two of the four α-helices in the bundle 
formed by SB10, the fucosyl group did not even bind to the lectin and the corresponding helix 
was only held in place by hydrophobic contacts within the bundle (Figure 3a, b, c). On the 
other hand, peptides SB12 and SB15 were observed in an extended, β-sheet like conformation 
engaging in four H-bonding contacts with LecB, providing a direct picture of an alternative, 
unfolded conformation (Figure 3d, e, f and Supplementary Figures S5.9-5.10). Both of these 
sequences belonged to the retro-inverso series and showed a less complete α-helical folding in 
20% TFE compared to the parent AMP, which might explain the absence of α-helical folding 
in the crystal (Table 1).  
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Figure 3. Details of the X-ray structures of α-helical AMPs in complex with LecB. (a) Electron density map of 
SB10, with Ca2+ atoms shown as magenta spheres and the bound LecB monomer as green cartoon. (b) Charge 
distribution within the 4-helix bundle formed by SB10. Backbone atoms are shown as cartoon. Hydrophobic side 
chains are colored brown and cationic side chains in blue. (c) 4-helix bundle of peptide SB10. Peptides are 
shown as spheres and bound lectin monomers are displayed as cartoon of the same color. (d) Electron density 
map of SB15 as in (a). (e) Details of the four stabilizing hydrogen bonds (black dashes) engaged on a LecB 
monomer by peptide SB15. Hydrophobic side chains are colored brown and cationic side chains in blue. (f) β-
sheet engagement of peptide SB15 bound to LecB. Peptides are shown as spheres and bound lectin monomers 
are displayed as cartoon of the same color. 
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SB4 α-helices are stabilized by bundle formation in the crystal 
The ten crystal structures from eight different peptides described above revealed twenty-four 
individual structures of short (11 to 13 residues) peptides. Assuming that all unresolved 
residues reflect disordered conformations, the overall α-helix content across all twenty-four 
resolved structures amounts to 76% on a per residue basis, which is significantly higher than 
the average α-helical content calculated from CD spectra showing unfolded conformations in 
water, which corresponds to the crystal environment (~10% α-helix content), and partially α-
helical conformations in the presence of TFE (~58% α-helix content in 20% TFE). 
Considering that there were almost no contacts between the peptides and the protein outside 
the fucose binding site in these structures, we hypothesized that α-helices might be stabilized 
by helix bundle formation in the crystal.  
 To test this hypothesis, we performed MD simulations using GROMACS(45) in 
explicit water for 1000 ns at 300 K starting from the 4-helix bundle of peptide SB4 as 
observed in the X-ray structure (PDB 6Q86), or from a single isolated α-helix. The 4-helix 
bundle was stable throughout the entire simulation as shown by overlays across the whole 
trajectory (Figure 4a), the stable number of hydrogen bonds and the low RMSD variance 
(Figure 4c/d, orange line). By contrast, the isolated α-helix rapidly unfolded under the same 
conditions and transitioned to a conformation containing a disordered N-terminus, a turn and 
a short intramolecular β-sheet at the C-terminus (Figure 4b and Figure 4c/d, blue line), which 
is consistent with CD data in water (Table 1 and Supplementary Table S2). The MD data thus 
clearly showed that the 4-helix bundle observed in the LecB crystal was stable on its own, and 
that its formation could explain the occurrence of α-helical conformations in the aqueous 
environment of the protein crystal despite the fact that the sequence does not fold significantly 
in pure water.   
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Figure 4. MD simulations of SB4 as 4-helix bundle and as single peptide in water. (a) Overlays of 100 states 
over the whole 1000 ns trajectory of a SB4 bundle. The average structure is shown as sticks, with the 100 
overlayed states as thin lines. Hydrophobic side chains are colored brown and cationic side chains blue. 
Backbone atoms are represented as cartoon. (b) Overlay of the major conformations from the whole 1000 ns 
trajectory of SB4 as single peptide in water. The average structure is shown as large sticks, with overlayed states 
as thin lines. Hydrophobic side chains are colored brown and cationic side chains blue. (c) Intramolecular 
Hydrogen bonds of a single helix within the bundle against the single peptide in water. (d) Root Mean Square 
Distances of the backbone atoms relative to the backbone atoms of the starting model. 
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H-bonding to the N-acyl group enhances α-helix amphiphilicity 
The presence of the C-fucosyl group might affect folding by enabling an additional α-helical 
backbone H-bond interaction involving its linker amide carbonyl group, which is absent in the 
free peptide. The crystallographic data showed that this additional H-bond was indeed present 
in 10 out of 18 individual structures of α-helical peptides, as illustrated here with the structure 
of LecB·SB6 which features both the H-bonded (Figure 5a) and the non H-bonded 
conformations (Figure 5b). 
To test if this additional α-helical H-bond might also participate in folding in an 
isolated α-helix, we performed MD simulations with SB2 and the C-fucosylated version SB4. 
We also investigated the N-acetyl (SB16), N-propanoyl (SB17) and N-octanoyl (SB18) 
derivatives, which we synthesized as new analogs of potential interest as antimicrobial 
peptides (Table 1). Indeed, although most AMPs have free N-termini, N-acylated AMPs can 
also show potent antimicrobial effects.(7, 46) We ran our MD simulations in explicit water 
solvent with 20% v/v TFE for 1000 ns starting from a model of each peptide in a pre-folded 
α-helix conformation derived from the structure of SB4 (PDB 6Q86) including the additional 
H-bond with the N-acyl group.  
The N-fucosylated peptide SB4 rapidly lost its acyl H-bond in the course of the 
simulation, leading to N-terminal conformations related to those of the free peptide SB2. In 
this conformation the N-terminal lysine side chain points to the opposite side of the α-helix 
relative to the cluster of cationic side chains (Figure 5c, d, f). By contrast, The N-acyl H-bond 
was preserved across the entire MD trajectory in SB16 (Figure 5e, f), SB17 and SB18 
(Supplementary Figures S6 and S7). These more stable trajectories resulted in an N-terminal 
conformation in which the lysine side chain at position 1 is rotated by 180° compared to SB2 
and SB4 and is located on the same side of the α-helix as the other cationic side chains. This 
arrangement of the side chains corresponded to an increased α-helix amphiphilicity compared 
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to SB2 and SB4. The conservation of the N-acyl H-bond in SB16-SB18 also induced a more 
rigid conformation of the N-terminal lysine side chain compared to SB2 and SB4 (Figure 5g).  
 
 
Figure 5. MD simulations with SB2, SB4 and SB16 in 20% TFE. The two conformations of peptide SB6 (PDB 
6Q6X) with (a) and without (b) the additional H-bond induced by the C-fucoside carbonyl moiety. Overlays of 
100 states over the whole 1000 ns trajectories of SB2 (c), SB4 (d) and SB16 (e) respectively. The average 
structure is shown as large sticks, with the 100 overlayed states as thin lines. Hydrophobic side chains are 
colored brown and cationic side chains blue. (f) H-bond counts. The N-terminal acetyl group is taking part in an 
additional H-bond compared to the fucosylated and non-fucosylated peptides. (g) The Root Mean Square 
fluctuations per atom show the high flexibility of the C-fucosyl group (cFuc) and the first lysine residue (k1) 
compared to the acetylated peptide. 
15 
 
N-acylated analogs of SB2 are potent antimicrobial and antibiofilm agents 
Our initial screening had shown that fucosylated SB4 and the N-acylated SB16-SB18 were as 
active as SB2 in terms of membrane disruption and as AMPs against P. aeruginosa PAO1 
(Table 1). This suggested that the N-terminal amino group in SB2 did not contribute 
significantly to activity, possibly because reduction by one positive charge was compensated 
by an increase in α-helix amphiphilicity induced by the additional H-bond as discussed above 
and pointed to the possibility to use N-acylation to modulate AMP activity.  
 A survey of antimicrobial activity across additional pathogenic bacteria showed that 
N-acylated AMPs SB4 and SB16-SB18 were as active as SB2 across the different strains, and 
even slightly more active in the case of Klebsiella pneumoniae-S, a pathogen which is 
generally difficult to control. Increasing peptide hydrophobicity by an N-terminal octanoyl 
group resulted in AMP SB18 showing the strongest antimicrobial activity (Table 2), however 
this sequence was unselective and strongly hemolytic (Table 1). Note that the free, non-
fucosylated D-peptide SB2 was slightly more active than its L-enantiomer SB1, which might 
reflect higher stability of the D-enantiomer in the culture medium where the L-enantiomer 
undergoes proteolysis (Supplementary Figure S2).   
Table 2. Minimal inhibitory concentration data.   
MICa) 
Strain SB1 SB2 SB4 SB16 SB17 SB18 
PAO1 2 1 4 2 2 2 
A. baumannii 19606 2 1 1 1 1 2 
K. pneumoniae-S 32 16 16 8 8 4 
E. coli (W3110) 1 0.5 1 1 1 2 
S. Epidermiditis n.d. 2 4 2 2 1 
MRSA* n.d. 4 8 4 4 2 
a) MIC (minimum inhibitory concentration) in μg/mL against wild type Gram-negative, Gram-positive and 
multidrug resistant (MDR, marked*) were measured by 1/2 serial dilutions on 96 well plates in Mueller-Hinton 
(MH) broth after incubation overnight at 37 °C. MIC values were measured in independent duplicates with at least 
two experiments giving the same value. 
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We further investigated inhibition of P. aeruginosa biofilms by SB4 since this peptide binds 
lectin LecB, and related multivalent(33, 39, 47)  and monovalent LecB ligands(48-50)  have 
been shown to inhibit biofilms from this bacterium. Indeed, SB4 inhibited P. aeruginosa 
biofilm formation, however the effect was comparable to the free D-enantiomeric peptide SB2 
(Figure 6). The L-enantiomer SB1 was again significantly less active against biofilms, 
probably due to proteolysis in the medium. We propose that the observed biofilm inhibition 
effect by SB2 and SB4 primarily results from a direct antibacterial effect mediated by 
membrane disruption. This hypothesis is supported by vesicle leakage experiments showing 
that both peptides induce significant membrane perturbations (Table 1).  
 
Figure 6. Relative absorbance readouts for Biofilm Inhibition on Pseudomonas aeruginosa PAO1 biofilm in 
M63 medium compared to untreated biofilms. Compound-containing wells were inoculated with the bacteria and 
the biofilms were allowed to grow 24-25 hours at 37° under static conditions. After washing, the biofilms were 
revealed with 0.5 mM WST-8 and 20 μM phenazine ethosulfate for 3 hours and the absorbance measured. The 
experiments were performed as triplicates. 
 
The membrane perturbation effects induced by SB2 and SB4 were further investigated by 
transmission electron microscopy (TEM). Images of P. aeruginosa, E. coli and A. baumannii 
cells showed that SB4 and SB2 induced similar morphological changes (Figure 7). After 
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treatment of PAO1 and E. coli with the peptides, vesicle-like structures and blebs were 
observed around the cells (blue arrows), consistent with a membrane disruptive mechanism. 
Peptides SB2 and SB4 also similarly affected the pili of A. baumannii (black arrows), one of 
its key virulence factors. In PAO1 and A. baumannii, dense aggregates were formed within 
the bacteria (orange arrows), which can be explained by peptide accumulation inside the cell 
and possibly aggregation with DNA. 
 
Figure 7. TEM images on Pseudomonas aeruginosa PAO1, E. coli and A. baumannii treated with 40 μg/mL 
SB2 and 40 μg/mL SB4 after 60 min. Arrows indicate effects of the peptides on bacterial membranes (blue 
arrows: vesicle like structures and blebs), cell contents (orange arrows: dense aggregates), and pili (black arrows: 
pili well present in control but less so in peptide treated cells). See Figure S4 for enlarged versions of the images.   
 
Conclusion 
Here we reported the first X-ray crystal structures of short α-helical AMPs at the example of 
analogs of the 13-residue AMP SB1. The structures were obtained in form of complexes of 
the fucosylated D-enantiomeric sequence SB4 with the bacterial lectin LecB. We also 
investigated shortened and retro-inverso sequences, resulting in a total of twenty-four 
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individual structures of eight different peptides. These structures show that these short AMPs 
form α-helices which assemble as two-helix or four-helix bundles displaying hydrophobic 
residues on the inside and cationic residues on the outside, without significant interaction with 
the lectin except for the anchoring fucosyl group bound at the fucose binding site. In two 
cases the peptide is observed in an extended β-sheet like conformation making four H-
bonding interaction with residues on the lectin surface. Overall 76% of the residues are 
observed within an α-helix, while the remaining residues are either not visible or in a different 
conformation. Molecular dynamics (MD) simulations show that α-helices are stabilized by 
bundle formation and suggest that the N-terminal acyl group present in the linker to the 
fucosyl group can extend the helix by one additional H-bond and increase α-helix 
amphiphilicity. Indeed, several N-acylated AMP displayed equivalent or stronger antibacterial 
effects compared to the free peptide. 
Methods 
Procedures for peptide synthesis, CD-spectroscopy, vesicle leakage experiments, 
microbiology, crystallization, X-ray data collection and refinement statistics, molecular 
dynamics, transmission electron microscopy, and analytical data for all peptides, are 
described in the supporting information.  
Associated Content 
Supporting Information. The supporting information is available free of charge on the ACS 
Publication website. Synthesis and characterization of all peptides, X-ray data collection 
tables, detailed procedures for CD spectroscopy, vesicle leakage experiments, molecular 
dynamics, microbiology (MIC and biofilm assays) and transition electron microscopy.  
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Accession Codes. Coordinates and structure factors of refined LecB complexed with 
fucosylated peptides are available from the Protein Data Bank with accession codes 6Q86 and 
6Q79 (SB4), 6Q6W (SB5), 6Q6X (SB6), 6Q8G (SB8), 6Q8H and 6Q87 (SB10), 6Q85 
(SB11), 6Q77 (SB12) and 6Q8D (SB15).  
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